Effect of 12-months testosterone replacement therapy on bone mineral density and markers of bone turnover in testicular cancer survivors – results from a randomized double-blind trial

References

• Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer: 2015 update. Eur Urol. 2015;68(6):1054–1068.
   PubMed Web of Science ®Google Scholar
• Cheng L, Albers P, Berney DM, et al. Testicular cancer. Nat Rev Dis Primers. 2018;4(1):29.
   PubMed Web of Science ®Google Scholar
• Oldenburg J, Fosså SD, Nuver J, et al. Testicular seminoma and non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6(Suppl 6):vi125–32.
   PubMedGoogle Scholar
• Ehrlich Y, Margel D, Lubin MA, et al. Advances in the treatment of testicular cancer. Transl Androl Urol. 2015;4(3):381–390.
   PubMedGoogle Scholar
• Fosså SD, Gilbert E, Dores GM, et al. Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst. 2007;99(7):533–544.
   PubMedGoogle Scholar
• Rajpert-De Meyts E, McGlynn KA, Okamoto K, et al. Testicular germ cell tumours. Lancet. 2016;387(10029):1762–1774.
   PubMed Web of Science ®Google Scholar
• Bandak M, Jørgensen N, Juul A, et al. A randomized double-blind study of testosterone replacement therapy or placebo in testicular cancer survivors with mild leydig cell insufficiency (Einstein-intervention). BMC Cancer. 2017;17(1):461.
   PubMedGoogle Scholar
• Nord C, Bjøro T, Ellingsen D, et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol. 2003;44(3):322–328.
   PubMed Web of Science ®Google Scholar
• Sprauten M, Brydøy M, Haugnes HS, et al. Longitudinal serum testosterone, luteinizing hormone, and follicle-stimulating hormone levels in a population-based sample of long-term testicular cancer survivors. J Clin Oncol. 2014; 32(6):571–578.
   PubMed Web of Science ®Google Scholar
• Sprauten M, Brydoy M, Haugnes HS, et al. Testosterone (T), luteinizing hormone (LH), and follicle stimulating hormone (FSH) levels in testicular cancer survivors (TCSs) 11 and 19 years after orchiectomy. J Clin Oncol. 2013; 1(15_suppl):4562–4562.
   Google Scholar
• Bandak M, Jørgensen N, Juul A, et al. Leydig cell dysfunction, systemic inflammation and metabolic syndrome in long-term testicular cancer survivors. Eur J Cancer. 2017;84:9–17.
   PubMed Web of Science ®Google Scholar
• Rochira V, Balestrieri A, Madeo B, et al. Osteoporosis and male age-related hypogonadism: role of sex steroids on bone (patho)physiology. Eur J Endocrinol. 2006;154(2):175–185.
   PubMed Web of Science ®Google Scholar
• Schubert M, Bullmann C, Minnemann T, et al. Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm Res. 2003;60(1):21–28.
   PubMed Web of Science ®Google Scholar
• Holmboe SA, Vradi E, Jensen TK, et al. The association of reproductive hormone levels and all-cause, cancer, and cardiovascular disease mortality in men. J Clin Endocrinol Metab. 2015;100(12):4472–4480.
   PubMed Web of Science ®Google Scholar
• Højer EG, Kreiberg M, Dehlendorff C, et al. Effect of testosterone replacement therapy on quality of life and sexual function in testicular cancer survivors with mild leydig cell insufficiency: results from a randomized double-blind trial. Clin Genitourin Cancer. 2022;20(4):334–343.
   PubMed Web of Science ®Google Scholar
• Eastell R, Pigott T, Gossiel F, et al. Diagnosis of endocrine disease: bone turnover markers: are they clinically useful? Eur J Endocrinol. 2018;178(1):R19–R31.
   PubMedGoogle Scholar
• Lorentzon M, Branco J, Brandi ML, et al. Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and follow-up of treatment for osteoporosis. Adv Ther. 2019; 36(10):2811–2824.
   PubMed Web of Science ®Google Scholar
• Tan RZ, Loh TP, Vasikaran S. Bone turnover marker monitoring in osteoporosis treatment response. Eur J Endocrinol. 2020;183(1):C5–C7.
   PubMed Web of Science ®Google Scholar
• Søeborg T, Frederiksen H, Johannsen TH, et al. Isotope-dilution turboflow-LC-MS/MS method for simultaneous quantification of ten steroid metabolites in serum. Clin Chim Acta. 2017;468:180–186.
   PubMed Web of Science ®Google Scholar
• Damgaard-Olesen A, Johannsen TH, Holmboe SA, et al. Reference ranges of 17-hydroxyprogesterone, DHEA, DHEAS, androstenedione, total and free testosterone determined by turboflow-LC-MS/MS and associations to health markers in 304 men. Clin Chim Acta. 2016;454:82–88.
   PubMed Web of Science ®Google Scholar
• Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666–3672.
   PubMed Web of Science ®Google Scholar
• Twisk J, Bosman L, Hoekstra T, et al. Different ways to estimate treatment effects in randomised controlled trials. Contemp Clin Trials Commun. 2018;10:80–85.
   PubMed Web of Science ®Google Scholar
• Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004;89(5):2085–2098.
   PubMed Web of Science ®Google Scholar
• Behre HM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 1997;82(8):2386–2390.
   PubMed Web of Science ®Google Scholar
• Wang C, Eyre DR, Clark R, et al. Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men–a clinical research center study. J Clin Endocrinol Metab. 1996;81(10):3654–3662.
   PubMed Web of Science ®Google Scholar
• Wang C, Swerdloff RS, Iranmanesh A, et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin Endocrinol . 2001;54(6):739–750.
   PubMed Web of Science ®Google Scholar
• Jørgensen NR, Møllehave LT, Hansen YBL, et al. Comparison of two automated assays of BTM (CTX and P1NP) and reference intervals in a Danish population. Osteoporos Int. 2017; 28(7):2103–2113.
   PubMed Web of Science ®Google Scholar
• Walsh JS, Marshall H, Smith IL, et al. Testosterone replacement in young male cancer survivors: a 6-month double-blind randomised placebo-controlled trial. PLOS Med. 2019;16(11):e1002960.
   PubMed Web of Science ®Google Scholar